Author: Nabil, Ahmed; Uto, Koichiro; Elshemy, Mohamed M.; Soliman, Reham; Hassan, Ayman A.; Ebara, Mitsuhiro; Shiha, Gamal
Title: Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020 Cord-id: 2g81sjnl Document date: 2020_7_20
ID: 2g81sjnl
Snippet: Coronaviruses are a group of enveloped viruses with non-segmented, single-stranded, and positive-sense RNA genomes. In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in Wuhan City, China. The World Health Organization (WHO) declared the coronavirus outbreak as a global pandemic in March 2020. Fever, dry cough and fatigue are found in the vast majority of all COVID-19 cases. Early diagnosis, treat
Document: Coronaviruses are a group of enveloped viruses with non-segmented, single-stranded, and positive-sense RNA genomes. In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in Wuhan City, China. The World Health Organization (WHO) declared the coronavirus outbreak as a global pandemic in March 2020. Fever, dry cough and fatigue are found in the vast majority of all COVID-19 cases. Early diagnosis, treatment and future prevention are keys to COVID-19 management. Currently, the unmet need to develop cost-effective point-of-contact test kits and efficient laboratory techniques for confirmation of COVID-19 infection has powered a new frontier of diagnostic innovation. No proven effective therapies or vaccines for SARS-CoV-2 currently exist. The rapidly increasing research regarding COVID-19 virology provides a significant number of potential drug targets. Remdesivir may be the most promising therapy up till now. On May 1, 2020, Gilead Sciences, announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational Remdesivir as a potential antiviral for COVID-19 treatment. On May 7, 2020, Gilead Sciences, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury® (Remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19 acute respiratory syndrome, under an exceptional approval pathway. Also, Corticosteroids are recommended for severe cases only to suppress the immune response and reduce symptoms, but not for mild and moderate patients where they are associated with a high-risk side effect. Based on the currently published evidence, we tried to highlight different diagnostic approaches, side effects and therapeutic agents that could help physicians in the frontlines.
Search related documents:
Co phrase search for related documents- absent mild and acute respiratory disease: 1, 2, 3
- absent mild and liver disease: 1, 2
- ace ang ii imbalance and acute ards respiratory distress syndrome: 1, 2
- ace ang ii imbalance and acute lung injury: 1
- ace ang ii imbalance and acute respiratory disease: 1
- acei angiotensin receptor and acute ards respiratory distress syndrome: 1, 2
- acei angiotensin receptor and acute kidney injury: 1, 2, 3, 4
- acei angiotensin receptor and acute lung injury: 1, 2
- acei angiotensin receptor and acute respiratory disease: 1, 2, 3, 4
- acei angiotensin receptor and liver disease: 1
- acei angiotensin receptor blocker and acute ards respiratory distress syndrome: 1
- acei angiotensin receptor blocker and acute kidney injury: 1
- acei angiotensin receptor blocker and acute lung injury: 1
- action need and acute ards respiratory distress syndrome: 1
- action need and acute respiratory disease: 1, 2, 3
- action need and liver disease: 1
- active metabolite and acute ards respiratory distress syndrome: 1, 2, 3
- active metabolite and acute kidney injury: 1
- active metabolite and acute lung injury: 1, 2
Co phrase search for related documents, hyperlinks ordered by date